GO:1903826 L-arginine transmembrane transport: Amino Acid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903826 describes the directed movement of L-arginine across a membrane, a process essential for amino acid homeostasis and cell signaling.
• L-arginine transport is mediated by specific membrane transporters such as SLC7A1 (CAT-1) and SLC38A9, which link arginine availability to mTORC1 signaling.
• Dysregulated L-arginine transport contributes to cancer progression, as oncogenic KRAS induces arginine auxotrophy and sensitivity to SLC7A1 inhibition in non-small cell lung cancer.
• The lysosomal arginine transporter SLC38A9 acts as a component of the mTORC1 signaling complex, sensing arginine and cholesterol to regulate cell growth.
• Experimental models for studying L-arginine transport include knockout, point-mutation, and overexpression cell lines, as well as CRISPR library screening for transporter genes.
• Understanding L-arginine transmembrane transport provides therapeutic opportunities, particularly in cancers dependent on exogenous arginine.
Description
L-arginine transmembrane transport (GO:1903826) is the directed movement of the amino acid L-arginine across a biological membrane. This process is fundamental to cellular physiology, as L-arginine serves not only as a building block for protein synthesis but also as a precursor for nitric oxide, polyamines, and creatine, and as a signaling molecule that regulates nutrient-sensing pathways. The transport of L-arginine across membranes is mediated by specialized transporter proteins that control its uptake and distribution within cells and organelles. Research into L-arginine transmembrane transport has gained prominence due to its critical role in mTORC1 signaling, a central regulator of cell growth and metabolism. The lysosomal transporter SLC38A9 senses arginine and cholesterol to activate mTORC1, thereby linking amino acid availability to anabolic processes. Additionally, the plasma membrane transporter SLC7A1 (also known as CAT-1) is essential for arginine uptake in many cell types, and its inhibition can selectively impair the growth of cancer cells with oncogenic KRAS mutations. These findings underscore the importance of L-arginine transport in both normal physiology and disease. This article provides a comprehensive overview of GO:1903826, covering its definition, biological significance, key genes and proteins, regulatory mechanisms, disease associations, and experimental approaches for studying L-arginine transmembrane transport. By integrating authoritative QuickGO data with verified PubMed literature, we aim to support researchers in understanding and investigating this essential biological process.
L-arginine transmembrane transport At A Glance
| GO ID | GO:1903826 |
|---|---|
| GO term | L-arginine transmembrane transport |
| Ontology | biological_process |
| Synonym | arginine transmembrane transport; arginine transport; L-arginine import; L-arginine transport; L-arginine uptake |
| Major function | Mediates the movement of L-arginine across membranes, influencing amino acid homeostasis and mTORC1 signaling |
| Key transporters | SLC7A1 (CAT-1), SLC38A9, and other members of the SLC family |
| Associated diseases | Cancer (e.g., non-small cell lung cancer), metabolic disorders |
| Research methods | CRISPR knockout, overexpression, transport assays, signaling studies |
What Is GO:1903826?
According to the Gene Ontology, GO:1903826 (L-arginine transmembrane transport) is defined as the directed movement of L-arginine across a membrane. This process encompasses the import, export, or distribution of L-arginine between cellular compartments or across the plasma membrane, mediated by specific transporter proteins.
Why Is L-arginine transmembrane transport Important in Cell Biology?
L-arginine transmembrane transport is crucial for maintaining intracellular arginine levels, which are essential for protein synthesis, nitric oxide production, and polyamine biosynthesis. Moreover, arginine transport is intimately linked to nutrient-sensing pathways, particularly mTORC1, which controls cell growth and proliferation. Dysregulation of arginine transport contributes to cancer development and metabolic diseases, making it a promising target for therapeutic intervention.
• Regulates intracellular L-arginine availability for protein synthesis and metabolic pathways.
• Controls mTORC1 signaling in response to amino acid and cholesterol levels.
• Supports nitric oxide production, impacting vascular function and immune responses.
• Influences polyamine synthesis, which is critical for cell proliferation.
• Plays a role in cancer cell growth, particularly in tumors with oncogenic KRAS.
• Contributes to metabolic reprogramming in cancer and other diseases.
• Provides potential targets for therapeutic intervention in cancer and metabolic disorders.
• Essential for normal development and tissue homeostasis.
• Involved in immune cell function and inflammation.
• Serves as a model for studying membrane transport mechanisms.
What Happens During L-arginine transmembrane transport?
Substrate Recognition and Binding
In simple terms: The transporter protein recognizes and grabs L-arginine on one side of the membrane.
L-arginine transmembrane transport begins with the specific recognition of L-arginine by a membrane transporter. Transporters such as SLC7A1 (CAT-1) and SLC38A9 exhibit high specificity for L-arginine, binding it through conserved amino acid residues in their transmembrane domains. This binding is often coupled to a concentration gradient or an electrochemical potential, driving the movement of arginine across the membrane.
Translocation Across the Membrane
In simple terms: The transporter changes shape to move L-arginine through the membrane.
Once bound, the transporter undergoes conformational changes that allow L-arginine to pass through the lipid bilayer. This translocation step is energy-dependent for some transporters, utilizing ATP or ion gradients, while others facilitate passive transport down the concentration gradient. The process is tightly regulated to maintain intracellular arginine homeostasis.
Release and Intracellular Distribution
In simple terms: L-arginine is released inside the cell or organelle for use.
After translocation, L-arginine is released into the cytoplasm or into specific organelles such as lysosomes. In lysosomes, SLC38A9-mediated arginine efflux is critical for mTORC1 activation, as arginine inside the lysosome signals amino acid sufficiency. This release step ensures that arginine is available for metabolic pathways and signaling.
Integration with Signaling Pathways
In simple terms: Arginine transport is connected to cell growth signals.
L-arginine transport is not merely a passive process; it is integrated with signaling pathways that sense nutrient availability. For example, SLC38A9 acts as a component of the lysosomal mTORC1 signaling complex, where it senses arginine and cholesterol to promote cell growth. Similarly, SLC7A1-mediated arginine uptake supports the metabolic demands of proliferating cells, and its inhibition can lead to growth arrest in certain cancers.
Key Genes Involved in GO:1903826 L-arginine transmembrane transport
The following genes encode transporters and related proteins that mediate or regulate L-arginine transmembrane transport.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC7A1 | High-affinity L-arginine transporter (CAT-1) at the plasma membrane | Target for inhibiting arginine uptake in KRAS-mutant cancers |
| SLC38A9 | Lysosomal arginine transporter and mTORC1 signaling component | Key sensor linking arginine and cholesterol to mTORC1 |
| SLC7A2 | L-arginine transporter (CAT-2) | Involved in immune cell function and inflammation |
| SLC7A3 | L-arginine transporter (CAT-3) | Expressed in brain and testis, potential role in neuronal function |
| SLC3A2 | Heavy chain subunit of system y+ transporters | Chaperone for SLC7A1 and related transporters |
| SLC7A5 | L-type amino acid transporter 1 (LAT1) | Transports large neutral amino acids, indirectly affects arginine metabolism |
| SLC7A11 | Cystine/glutamate transporter | Modulates redox balance and arginine availability |
| SLC25A29 | Mitochondrial arginine transporter | Regulates mitochondrial arginine for urea cycle and polyamine synthesis |
| SLC25A15 | Mitochondrial ornithine transporter | Links arginine metabolism to urea cycle |
| NOS1 | Neuronal nitric oxide synthase | Utilizes L-arginine to produce nitric oxide |
| NOS2 | Inducible nitric oxide synthase | Produces nitric oxide from L-arginine in immune responses |
| NOS3 | Endothelial nitric oxide synthase | Regulates vascular tone via L-arginine-derived nitric oxide |
| ARG1 | Arginase 1 | Competes with NOS for L-arginine, affecting transport demand |
| ARG2 | Arginase 2 | Mitochondrial arginase, regulates arginine availability |
| ODC1 | Ornithine decarboxylase | Converts ornithine (from arginine) to polyamines |
| ASS1 | Argininosuccinate synthase 1 | Involved in arginine biosynthesis, affects transport dependency |
| ASL | Argininosuccinate lyase | Catalyzes final step of arginine synthesis |
How Is L-arginine transmembrane transport Regulated?
L-arginine transmembrane transport is regulated at multiple levels. The expression and activity of transporters such as SLC7A1 and SLC38A9 are modulated by nutrient availability, growth factors, and stress signals. For instance, growth factor stimulation can increase L-arginine transport activity in cancer cells. Additionally, the mTORC1 pathway itself feeds back to regulate transporter expression, ensuring coordinated control of amino acid uptake and cell growth. Oncogenic KRAS can induce arginine auxotrophy by altering the expression of arginine transporters and metabolic enzymes, making cells dependent on exogenous arginine.
L-arginine transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A1 | Non-small cell lung cancer with KRAS mutations | KRAS-mutant NSCLC cell lines with SLC7A1 knockout or inhibition |
| SLC38A9 | Cancer metabolism and mTORC1-driven growth | SLC38A9 knockout cells to study mTORC1 signaling |
| SLC25A29 | Hyperammonemia and urea cycle disorders | Liver-specific knockout mouse models |
| NOS2 | Inflammatory diseases and septic shock | Macrophage-specific knockout or overexpression |
| ARG1 | Arginase deficiency and immune suppression | ARG1 knockout mice or cell lines |
L-arginine Transport in Cancer
Dysregulated L-arginine transport is increasingly recognized as a hallmark of cancer. Oncogenic KRAS mutations induce arginine auxotrophy in non-small cell lung cancer, rendering cells dependent on SLC7A1-mediated arginine uptake for survival and proliferation. Inhibition of SLC7A1 selectively impairs the growth of KRAS-mutant cancer cells, highlighting a therapeutic vulnerability. Furthermore, SLC38A9-mediated lysosomal arginine sensing promotes mTORC1 activation, supporting anabolic metabolism in cancer cells.
Metabolic and Immune Disorders
Altered L-arginine transport contributes to metabolic and immune disorders. In immune cells, arginine transport is essential for nitric oxide production and T cell function. Dysregulation of arginine transporters can lead to impaired immune responses and chronic inflammation. Additionally, mutations in mitochondrial arginine transporters such as SLC25A29 can disrupt urea cycle function and cause hyperammonemia.
Neurological Implications
L-arginine transport in the brain is critical for neurotransmitter synthesis and nitric oxide signaling. Transporters like SLC7A3 are expressed in neurons and may influence synaptic function. Disruptions in arginine transport have been implicated in neurodegenerative conditions, although the exact mechanisms require further investigation.
From L-arginine transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC7A1 mediate L-arginine uptake in cancer cells? | SLC7A1 knockout cell lines (e.g., CRISPR-Cas9) |
| How does SLC38A9 sense arginine for mTORC1 activation? | SLC38A9 point mutations or knock-in of sensor domain mutants |
| What is the effect of SLC7A1 overexpression on cell growth? | SLC7A1 overexpression cell lines |
| Can SLC7A1 inhibition selectively target KRAS-mutant cancers? | Patient-derived xenografts or isogenic cell lines with KRAS mutations |
| How does mitochondrial arginine transport affect urea cycle? | SLC25A29 knockout hepatocytes or mouse models |
| What is the role of arginine transport in immune cells? | Conditional knockout of SLC7A2 in T cells or macrophages |
How to Study the L-arginine transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled arginine uptake | Transport activity | Characterizing transporter kinetics and specificity |
| CRISPR-Cas9 knockout | Gene function | Assessing the role of specific transporters in arginine uptake |
| Western blot | Protein expression and signaling | Monitoring mTORC1 activity and transporter levels |
| Immunofluorescence | Subcellular localization | Visualizing transporter localization (e.g., lysosomal SLC38A9) |
| Metabolomics | Metabolite levels | Quantifying arginine and related metabolites |
| RNA-seq | Transcriptional changes | Identifying compensatory transporter expression |
| Proteomics | Protein interactions | Identifying components of transporter complexes |
| Patch-clamp electrophysiology | Ion channel activity | Studying electrogenic transporters (if applicable) |
Transport Assays
Radiolabeled L-arginine uptake assays are used to measure transport activity in cells. These assays can quantify the rate of arginine influx and efflux, and are often combined with inhibitors to identify specific transporters. For example, system y+ activity can be measured using L-[3H]arginine in intestinal cells.
Genetic Knockout and Knockdown
CRISPR-Cas9 knockout or siRNA knockdown of specific transporter genes (e.g., SLC7A1, SLC38A9) allows researchers to assess their contribution to L-arginine transport and downstream signaling. These approaches have been used to demonstrate the essential role of SLC7A1 in KRAS-mutant cancer cell growth.
Signaling Pathway Analysis
Western blotting and immunofluorescence are used to monitor mTORC1 activity (e.g., phosphorylation of S6K1 and 4E-BP1) in response to arginine transport modulation. Such studies have revealed the role of SLC38A9 in lysosomal arginine sensing.
Metabolomics and Flux Analysis
Mass spectrometry-based metabolomics can quantify intracellular arginine and its metabolites (e.g., citrulline, ornithine, polyamines) to assess the impact of transport on cellular metabolism. This approach is valuable for understanding how arginine transport supports cancer cell proliferation.
How CRISPR Can Be Used to Study GO:1903826 L-arginine transmembrane transport
Knockout
CRISPR-Cas9 knockout of L-arginine transporter genes (e.g., SLC7A1, SLC38A9) is a powerful approach to study their function. Knockout cells exhibit reduced arginine uptake and impaired downstream signaling, such as decreased mTORC1 activity. These models are essential for validating transporter specificity and identifying compensatory mechanisms.
Point Mutation
Point mutations can be introduced into transporter genes to dissect structure-function relationships. For example, mutating key residues in the substrate-binding pocket of SLC38A9 can abolish arginine sensing while preserving lysosomal localization. Such models help identify critical amino acids for transport activity and regulation.
Knock-in
Knock-in of tagged transporters (e.g., GFP-SLC38A9) allows real-time visualization and biochemical purification. Tagged knock-in cell lines are valuable for studying transporter trafficking, interactions, and dynamics in response to nutrients.
Overexpression
Overexpression of L-arginine transporters (e.g., SLC7A1) can increase arginine uptake and enhance cell proliferation under limiting conditions. This approach is used to study the consequences of elevated transport on metabolism and signaling, and to model diseases with transporter upregulation.
How EDITGENE Supports L-arginine transmembrane transport Research
Researchers studying L-arginine transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in arginine uptake, signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for L-arginine transmembrane transport research.
Frequently Asked Questions About L-arginine transmembrane transport
What is L-arginine transmembrane transport?
L-arginine transmembrane transport (GO:1903826) is the directed movement of the amino acid L-arginine across a biological membrane, mediated by specific transporter proteins.
What genes are involved in L-arginine transmembrane transport?
Key genes include SLC7A1 (CAT-1), SLC38A9, SLC7A2, SLC7A3, and SLC3A2, among others.
How is L-arginine transport linked to mTORC1 signaling?
The lysosomal transporter SLC38A9 senses arginine and cholesterol to activate mTORC1, thereby linking amino acid availability to cell growth.
What diseases are associated with defective L-arginine transport?
Dysregulated L-arginine transport is implicated in cancer (e.g., KRAS-mutant lung cancer), metabolic disorders, and immune dysfunction.
Can L-arginine transport be targeted for cancer therapy?
Yes, inhibiting SLC7A1-mediated arginine uptake selectively impairs KRAS-mutant cancer cell growth, representing a potential therapeutic strategy.
What methods are used to study L-arginine transmembrane transport?
Common methods include radiolabeled uptake assays, CRISPR knockout, Western blotting, metabolomics, and immunofluorescence.
What is the role of SLC38A9 in arginine transport?
SLC38A9 is a lysosomal arginine transporter that acts as a component of the mTORC1 signaling complex, sensing arginine and cholesterol.
How does oncogenic KRAS affect arginine transport?
Oncogenic KRAS induces arginine auxotrophy, making cancer cells dependent on exogenous arginine uptake via transporters like SLC7A1.
Are there mitochondrial L-arginine transporters?
Yes, SLC25A29 is a mitochondrial arginine transporter involved in urea cycle and polyamine metabolism.
What CRISPR models are available for studying L-arginine transport?
EDITGENE offers knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening for L-arginine transport genes.
Conclusion
L-arginine transmembrane transport (GO:1903826) is a fundamental biological process that controls intracellular arginine levels and integrates with key signaling pathways such as mTORC1. Its dysregulation contributes to cancer, metabolic disorders, and immune dysfunction, making it a compelling target for therapeutic intervention. Understanding the molecular mechanisms and regulation of L-arginine transporters is essential for developing novel treatments. By leveraging CRISPR-based models and advanced screening technologies, researchers can dissect the roles of specific transporters and identify new therapeutic opportunities. EDITGENE provides comprehensive services to support these efforts, from knockout and point mutation cell lines to library screening and bioinformatics analysis.
References
- 1. Castellano BM et al.. 2017. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex.. Science 355(6331):1306-1311 PMID: 28336668
- 2. Jung JW et al.. 2019. Transmembrane 4 L Six Family Member 5 Senses Arginine for mTORC1 Signaling.. Cell Metab 29(6):1306-1319.e7 PMID: 30956113
- 3. Gai X et al.. 2024. Oncogenic KRAS Induces Arginine Auxotrophy and Confers a Therapeutic Vulnerability to SLC7A1 Inhibition in Non-Small Cell Lung Cancer.. Cancer Res 84(12):1963-1977 PMID: 38502865
- 5. Horn R. 2005. Electrifying phosphatases.. Sci STKE 2005(307):pe50 PMID: 16249403
- 6. Cendan JC et al.. 1995. Characterization and growth factor stimulation of L-arginine transport in a human colon cancer cell line.. Ann Surg Oncol 2(3):257-65 PMID: 7641023
- 7. Pan M et al.. 2002. Specific reversible stimulation of system y(+) L-arginine transport activity in human intestinal cells.. J Gastrointest Surg 6(3):379-86 PMID: 12022990
- 8. De Geyter J et al.. 2019. Inner Membrane Translocases and Insertases.. Subcell Biochem 92:337-366 PMID: 31214992
